Dall'Olio R, Roncada P, Vaccheri A, Gandolfi O, Montanaro N
Institute of Pharmacology, University of Bologna, Italy.
Psychopharmacology (Berl). 1989;98(3):342-6. doi: 10.1007/BF00451685.
Several studies have indicated that the D2 dopamine receptors mediate the antidopaminergic activity of the neuroleptics; nevertheless, the selective blocker (-)-sulpiride weakly inhibits dopamine-mediated behaviour. The present study investigated whether the concomitant injection of doses of the D1 antagonist SCH 23390, which by themselves are without effect, would enable (-)-sulpiride to express fully neuroleptic activity in the rat. The benzamide YM 09151-2 that strongly inhibits dopamine-mediated behaviour was also studied. Rats receiving different doses of (-)-sulpiride, YM 09151-2 and SCH 23390 given alone or in combination were tested for exploratory activity, apomorphine-induced stereotyped behaviour and hyperactivity elicited by the D2 agonist LY 171555. When given alone, (-)-sulpiride (10, 20 and 40 mg/kg IP) had no effect on exploratory activity and stereotypy. When (-)-sulpiride was administered in combination with an ineffective dose of SCH 23390 (5 micrograms/kg) both responses were significantly inhibited. The combined administration of subthreshold doses of (-)-sulpiride (2.5 mg/kg) and SCH 23390 (2.5 micrograms/kg) significantly inhibited hypermotility induced by LY 171555. Moreover, the combined administration of ineffective doses of YM 09151-2 with subthreshold doses of SCH 23390 strongly inhibited all the behavioural responses. The results indicate that SCH 23390 allowed (-)-sulpiride to exhibit a wider spectrum of neuroleptic activity and potentiated the antidopaminergic activity of YM 09151-2.
多项研究表明,D2多巴胺受体介导了抗精神病药物的抗多巴胺能活性;然而,选择性阻断剂(-)-舒必利对多巴胺介导的行为仅有微弱抑制作用。本研究调查了同时注射本身无作用的D1拮抗剂SCH 23390剂量,是否能使(-)-舒必利在大鼠中充分表现出抗精神病活性。还对强烈抑制多巴胺介导行为的苯甲酰胺YM 09151-2进行了研究。单独或联合给予不同剂量(-)-舒必利、YM 09151-2和SCH 23390的大鼠,接受了探索性活动、阿扑吗啡诱导的刻板行为以及D2激动剂LY 171555引发的多动测试。单独给予时,(-)-舒必利(10、20和40mg/kg腹腔注射)对探索性活动和刻板行为无影响。当(-)-舒必利与无效剂量的SCH 23390(5μg/kg)联合给药时,两种反应均受到显著抑制。阈下剂量的(-)-舒必利(2.5mg/kg)和SCH 23390(2.5μg/kg)联合给药显著抑制了LY 171555诱导的多动。此外,无效剂量的YM 09151-2与阈下剂量的SCH 23390联合给药强烈抑制了所有行为反应。结果表明,SCH 23390使(-)-舒必利表现出更广泛的抗精神病活性谱,并增强了YM 09151-2的抗多巴胺能活性。